Hydrochloride pioglitazone decreases urinary TGF-β1 excretion in type 2 diabetics

Authors


  • Randomized clinical trial

Shan-dong Ye, Medical Doctor; Professor, Department of Endocrinology, Anhui Provincial Hospital Affiliated to Anhui Medical University, NO 17, Lujiang Road, Hefei, China, 230001. Tel.: 86 551 2283301; fax: 86 551 2283292; e-mail: ysd6464@yahoo.com.cn

Abstract

Eur J Clin Invest 2010; 40 (7): 571–574

Abstract

Background  Thiazolidinediones (TZDs) exert a number of direct reno-protection beyond its hypoglycaemic effect in type 2 diabetics, which may be partly related to its anti-fibrosis and anti- inflammatory action.

Materials and methods  A total of 98 type 2 diabetics with fasting blood glucose (FBG) between 7·0 and 13·0 mmol L−1 and glycated haemoglobin A1c (HbA1c) ≥ 7·0% were randomly assigned to add pioglitazone (group DP) or sulfonylurea (group DS) for 12 weeks. FBG, HbA1c, serum creatinine (SCr) and blood urea nitrogen (BUN), and urinary TGF-β1, albumin (UALB) and creatinine (UCr) were determined at the basal and the 12th week.

Results  Fasting blood glucose, HbA1c and urinary TGF-β1/UCr ratio (UTCR) were obviously decreased in both groups after 12 weeks treatment; UALB/UCr ratio (UACR) decreased obviously in group DP (P < 0·01), while slightly in group DS. UACR and UTCR in group DP were significantly lower than those in group DS after treatment, while FBG and HbA1c had no statistical differences between the two groups. In addition, UTCR had positive correlation with UACR (r = 0·367, P < 0·01).

Conclusions  Pioglitazone decreases urinary TGF-β1 excretion in type 2 diabetics, which may be partly contributed to its direct reno-protection.

Ancillary